ComGen Biopharmaceutical
Shanghai
About ComGen Biopharmaceutical
Kangjing Bio focuses on the research and development of innovative drugs for the immunotherapy of autoimmune diseases and tumors. A round of financing of nearly 100 million yuan has been completed. This round of financing was jointly led by Sequoia China and Yahui Investment, followed by Fuchuang Investment and Renyou Investment. For this transaction, Hejun Capital and Chenrui Capital acted as financial advisors. This round of financing will be mainly used for phase I clinical trials of complement inhibitors under research on new targets, the advancement of other pipeline drugs, and the further consolidation of the application of innovative drug research and development platforms based on the complement system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2021)
- Website: comgenpharma.com
- Phone: +86-21-68822018
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/comgen-biopharmaceutical-2226328 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.